 BOULDER, Colo., July 02, 2020 GLOBE NEWSWIRE -- miRagen Therapeutics, Inc. MGEN, a clinical-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, today announced that on July 1, 2020 it received written notice from the Nasdaq Listing Qualifications Staff of the NASDAQ Stock Market LLC Nasdaq stating that the Company regained compliance with the applicable Nasdaq minimum bid price continued listing requirement and the matter is now closed. The Company had previously been notified by Nasdaq on October 28, 2019 that it was not in compliance with the minimum bid price requirement because its common stock failed to maintain a minimum bid price of 1.00 for 30 consecutive business days. 